Angle PLC - Guildford, England-based liquid biopsy company - Notes largest study presented by Molecular Oncology Group at the Medical University of Vienna at conference in Greece shows how gene expression analysis of circulating tumour cells, isolated by the Parsortix system, can be used in pharma drug trials for longitudinal patient monitoring and to guide treatment selection. "Gene expression analysis of genes expressed on CTCs isolated from successive blood draws correlated closely with significantly improved progression free survival and response to therapy," it says.
In second study, researchers evaluated the detection of tumour protein p53 as a new marker for circulating tumour cell detection in small cell lung cancer, and the third study saw researchers perform qPCR molecular analysis on the circulating tumour cells captured by the Parsortix system in samples from 118 non-small cell lung cancer patients and 30 healthy volunteers.
It says: "These studies demonstrate that CTC analysis before and during treatment can provide non-invasive monitoring of cancer patients throughout their treatment pathway and that CTC gene expression profiles can determine progression free survival and response to therapy."
Current stock price: 120.00 pence
Year-to-date change: up sharply from 47.75p
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Angle (AGL)